相关实验视频

Updated: Jan 7, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

BTLA:癌症免疫疗法中的新兴免疫检查点目标

Ming-Cheng Chang¹, Wan-Chi Lee¹, Yi-Jou Tai^2,3

¹Department of Isotope Application Research, National Atomic Research Institute, No. 1000, Wenhua Rd., Longtan Dist., Taoyuan City 325207, Taiwan.

Pharmaceuticals (Basel, Switzerland)

|December 31, 2025

概括

B和T淋巴细胞减弱剂 (BTLA) 是免疫反应的关键调节者. 针对BTLA提供了一种有希望的策略,以克服当前免疫疗法耐药的癌症的免疫逃避.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
分子信号传输的方法

背景情况:

B和T淋巴细胞减弱剂 (BTLA) 是一种共抑制受体,在免疫激活和耐受性方面具有双重作用.
BTLA与HVEM的双向相互作用创造了一个复杂的信号网络,影响瘤微环境.
改变BTLA表达与瘤免疫逃避和各种癌症患者预后不佳相关.

研究的目的:

提供BTLA在瘤免疫中的结构,信号和功能的全面审查.
讨论在癌症治疗中准BTLA的治疗潜力.
探索BTLA向治疗的挑战和未来方向.

主要方法:

关于BTLA在癌症免疫力中的作用的文献综述.
对BTLA的分子相互作用和信号通路的分析.
综合关于BTLA向治疗策略的当前研究.

主要成果:

BTLA的独特特性使其与PD-1和CTLA-4等其他免疫检查点区别开来.
失调的BTLA有助于瘤免疫逃逸,使其成为新型治疗的目标.
BTLA调制是增强治疗耐药瘤免疫疗法的潜在策略.

结论:

BTLA是癌症免疫疗法的重要新兴标,特别是对于对现有治疗不反应的瘤.
对BTLA的机制和向治疗的进一步研究对于改善癌症治疗结果至关重要.
利用BTLA调制为推进癌症免疫治疗提供了前途.

关键词:

B和T淋巴细胞减弱器这就是BTLA.癌症免疫疗法免疫疗法临床应用临床应用免疫检查点是一个检查点.瘤学在瘤学方面.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...